Shankar Musunuri - Jan 17, 2023 Form 4 Insider Report for Ocugen, Inc. (OCGN)

Signature
/s/ Shankar Musunuri by Jessica Crespo, his attorney-in-fact
Stock symbol
OCGN
Transactions as of
Jan 17, 2023
Transactions value $
-$77,000
Form type
4
Date filed
1/19/2023, 03:12 PM
Previous filing
Jan 5, 2023
Next filing
Jan 4, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCGN Common Stock Options Exercise $51K +100K +4.49% $0.51 2.33M Jan 17, 2023 Direct
transaction OCGN Common Stock Sale -$128K -100K -4.3% $1.28 2.23M Jan 17, 2023 Direct F1, F2
holding OCGN Common Stock 1.15M Jan 17, 2023 By: KVM Holdings, LLC F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCGN Option (Right to Buy) Options Exercise $0 -100K -23.44% $0.00 327K Jan 17, 2023 Common Stock 100K $0.51 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.27 to $1.31. The Reporting Person undertakes to provide Ocugen, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The Reporting Person is a member and officer of KVM Holdings, LLC and has voting and investment power over the shares held by KVM Holdings, LLC.
F4 The options, initially representing a right to purchase 933,528 shares, vest and become exercisable in equal annual installments over three years commencing on January 2, 2021, subject to continued service with the Company on the applicable vesting dates.